摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-fluoro-2-methylindol-5-yloxy)-4-(pyridin-4-ylmethyl)phthalazine | 397842-88-5

中文名称
——
中文别名
——
英文名称
1-(4-fluoro-2-methylindol-5-yloxy)-4-(pyridin-4-ylmethyl)phthalazine
英文别名
1-(4-fluoro-2-methylindol-5-yloxy)-4-(4-pyridylmethyl)phthalazine;1-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-4-(pyridin-4-ylmethyl)phthalazine
1-(4-fluoro-2-methylindol-5-yloxy)-4-(pyridin-4-ylmethyl)phthalazine化学式
CAS
397842-88-5
化学式
C23H17FN4O
mdl
——
分子量
384.413
InChiKey
JOWQCTXBMHNGDA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.5
  • 重原子数:
    29
  • 可旋转键数:
    4
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    63.7
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为产物:
    描述:
    4-氟-5-羟基-2-甲基吲哚瓦他拉尼中间体caesium carbonate 作用下, 以 二氯甲烷乙酸乙酯N,N-二甲基甲酰胺 为溶剂, 以41%的产率得到1-(4-fluoro-2-methylindol-5-yloxy)-4-(pyridin-4-ylmethyl)phthalazine
    参考文献:
    名称:
    Chemical compounds
    摘要:
    本发明涉及具有以下化学式(I)的化合物:其中:环C是9或10元杂环脂环芳烃基团,至少含有一个氮原子连接到Z,并可选地含有另外1-3个杂原子,独立选择自O、S和N,条件是环C不是喹唑啉、喹啉或茴香啉基团;G1、G2、G3、G4和G5中的任何一个是氮,其他四个是—CH—;或者G1、G2、G3、G4和G5都是—CH—;Z是—O—、NH—、—S—、CH2—或直接取代基,R1可以连接到吲哚、氮杂吲哚或吲唑基团的任何自由碳原子处;m是0到2的整数;Rb代表氢或本文中定义的另一个值;R1代表氢、羟基、卤代基、C1-4烷基或本文中定义的任何其他值;R2代表氢、羟基、卤代基、氰基、硝基、三氟甲基、C1-3烷基、C1-3烷氧基、C1-3烷基硫基、—NR3R4(其中R3和R4,可能相同也可能不同,各自代表氢或C1-3烷基),或R5X1—(其中R5和X1如本文所定义),以及其盐,以及制备此类化合物的方法,制备药物组合物。
    公开号:
    US20030207878A1
点击查看最新优质反应信息

文献信息

  • INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY
    申请人:AstraZeneca AB
    公开号:EP1311500A2
    公开(公告)日:2003-05-21
  • [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSES CHIMIQUES
    申请人:ASTRAZENECA AB
    公开号:WO2002012227A2
    公开(公告)日:2002-02-14
    The invention relates to compounds of the formula (I): wherein: ring C is 9 or 10-membered bicyclic heteroaromatic group containing at least one nitrogen atom in the ring attached to Z and optionally containing a further 1-3 heteroatoms, selected independently from O, S and N, with the proviso that ring C is not a quinazoline, quinoline or cinnoline group; either any one of G1, G2, G3, G4 and G5 is nitrogen and the other four are -CH-; or G1, G2, G3, G4 and G5 are all -CH-; Z is -O-, NH-, -S-, CH2- or a direct bond, Z is linked to any one of G1, G2, G3 and G4; n is an integer from 0 to 5; any of the substituents R1 may be attached at any free carbon atom of the indole, azaindole or indazole group; m is an integer from 0 to 2; R?b, R1 and R2¿ are as defined herein and salts thereof, which are useful for the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.
  • Chemical compounds
    申请人:——
    公开号:US20030207878A1
    公开(公告)日:2003-11-06
    The invention relates to compounds of the formula (I): wherein: ring C is 9 or 10-membered bicyclic heteroaromatic group containing at least one nitrogen atom in the ring attached to Z and optionally containing a further 1-3 heteroatoms, selected independently from O, S, and N, with the proviso that ring C is not a quinazoline, quinoline or cinnoline group; either any one of G 1 , G 2 , G 3 , G 4 and G 5 is nitrogen and the other four are —CH—; or G 1 , G 2 , G 3 , G 4 and G 5 are all —CH—; Z is —O—, NH—, —S—, CH 2 — or a direct substituents R 1 may be attached at any free carbon atom of the indole, azaindole or indazole group; m is an integer from 0 to 2; R b represents hydrogen or another value as defined herein; R 1 represents hydrogen, hydroxy, halogeno, C 1-4 alkyl, or any other value as defined herein; R 2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylsulphanyl, —NR 3 R 4 (wherein R 3 and R 4 , which may be the same or different, each represents hydrogen or C 1-3 alkyl), or R 5 X 1 — (wherein R 5 and X 1 are as defined herein) and salts thereof, processes for the preparation of such compounds, pharmaceutical compositions
    本发明涉及具有以下化学式(I)的化合物:其中:环C是9或10元杂环脂环芳烃基团,至少含有一个氮原子连接到Z,并可选地含有另外1-3个杂原子,独立选择自O、S和N,条件是环C不是喹唑啉、喹啉或茴香啉基团;G1、G2、G3、G4和G5中的任何一个是氮,其他四个是—CH—;或者G1、G2、G3、G4和G5都是—CH—;Z是—O—、NH—、—S—、CH2—或直接取代基,R1可以连接到吲哚、氮杂吲哚或吲唑基团的任何自由碳原子处;m是0到2的整数;Rb代表氢或本文中定义的另一个值;R1代表氢、羟基、卤代基、C1-4烷基或本文中定义的任何其他值;R2代表氢、羟基、卤代基、氰基、硝基、三氟甲基、C1-3烷基、C1-3烷氧基、C1-3烷基硫基、—NR3R4(其中R3和R4,可能相同也可能不同,各自代表氢或C1-3烷基),或R5X1—(其中R5和X1如本文所定义),以及其盐,以及制备此类化合物的方法,制备药物组合物。
查看更多